U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07486869) titled 'Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study' on March 16.
Brief Summary: This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Dermatomyositis
Dermatomyositis Sine Myositis
Dermatomyositis With Myopathy
D...